Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts
Gaspar J. Kitange(Hormel (United States)), Jann N. Sarkaria(Mayo Clinic in Arizona), Jenny L. Pokorny(Mayo Clinic), Ling Cen(The Ohio State University), Shiv K. Gupta(Mayo Clinic), Raúl Urrutia(Centre National de la Recherche Scientifique), Gwen Lomberk(Medical College of Wisconsin), Paul A. Decker(University of California, San Francisco), Ann C. Mladek(Mayo Clinic), Mark A. Schroeder(MACOM (United States)), Brett L. Carlson(University of California, San Francisco), Wenting Wu(East China Normal University)
Cited by 151
Related Papers
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
|Neuro-Oncology|2008|387
Drivers, trends, and potential impacts of long-term coastal reclamation in China from 1985 to 2010
|Estuarine Coastal and Shelf Science|2016|333
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
|Journal of Clinical Oncology|2008|275
Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes
|Nature Communications|2018|275